<DOC>
	<DOCNO>NCT00421551</DOCNO>
	<brief_summary>The purpose study evaluate whether monotherapy boost darunavir able maintain virological success 48 week comparison standard therapy 2 INTI + darunavir/r HIV infect patient full viral suppression .</brief_summary>
	<brief_title>Study Comparing Efficacy Safety Darunavir Boosted With Ritonavir HART With 2 NRTI Darunavir Boosted With Ritonavir HIV-1 Infected Patients ANRS136</brief_title>
	<detailed_description>The chronicity disease require treatment decade , long-term adverse event associate standard combine antiretroviral therapy , emphasize need simpler , alternative treatment strategy HIV infection . The goal antiretroviral therapy 2006 durability treatment less toxicity reduce exposure drug . Previous study show single boost PI maintenance therapy lopinavir ( LPV/r ) , effective maintain virological efficacy . Furthermore , case virological failure , limited resistance describe . darunavir/r , new PI , show highly potent , exhibit high genetic barrier resistance appear well tolerate . This study aim evaluate whether darunavir/r represent potential strategy therapeutic single therapy patient full virologic suppression At entry , subject HIV RNA 50 cp/ml switch current therapy 2 NRTI IP , 2 NRTI NNRTI , 3 NRTI darunavir/r 2 NRTIs 8 week ( Phase I ) . If patient remain 50 cp/ml intolerance darunavir week -4 , include phase II randomize either receive darunavir/r alone continue 2 NRTI darunavir/r W48 ( Phase II ) . Patients monitor W4 , W8 every 8 week W48 primary endpoint . To evaluate durability safety strategy , patient follow W96</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Confirmed HIV1 infection . Documented level HIV1 RNA initiation antiretroviral treatment Prior antiretroviral regimen , include least 2 NRTIs combine 1 PI NNRTI third NRTI least 18 month prior study entry . CD4 count 200 cell per mm3 great . Viral load 400 copy per ml within 18 month prior entry 50 copy per mL entry . Willing use acceptable method contraception Previous virological failure prior PIbased regimen . Prior therapy darunavir . HIV2 infect patient . Absence document level HIV1 RNA initiation antiretroviral treatment Hepatitis B C infection within 90 day prior study entry . Therapies include interferon , interleukin2 , cytotoxic chemotherapy immunosuppressor study entry . Serious acute illness require systemic treatment hospitalization 14 day prior study entry . Treatment active AIDS defining opportunistic infection within 30 day prior screen Drug alcohol use dependence would interfere compliance . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>darunavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>treatment experience</keyword>
</DOC>